DOCSLIB.ORG

List of Section 13F Securities, Fourth Quarter 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
List of Section 13F Securities, Fourth Quarter 2019 List of Section 13F Securities Fourth Quarter FY 2019 Copyright (c) 2020 American Bankers Association. CUSIP Numbers and descriptions are used with permission by Standard & Poors CUSIP Service Bureau, a division of The McGraw-Hill Companies, Inc. All rights reserved. No redistribution without permission from Standard & Poors CUSIP Service Bureau. Standard & Poors CUSIP Service Bureau does not guarantee the accuracy or completeness of the CUSIP Numbers and standard descriptions included herein and neither the American Bankers Association nor Standard & Poor's CUSIP Service Bureau shall be responsible for any errors, omissions or damages arising out of the use of such information. U.S. Securities and Exchange Commission OFFICIAL LIST OF SECTION 13(f) SECURITIES USER INFORMATION SHEET General This list of “Section 13(f) securities” as defined by Rule 13f-1(c) [17 CFR 240.13f-1(c)] is made available to the public pursuant to Section13 (f) (3) of the Securities Exchange Act of 1934 [15 USC 78m(f) (3)]. It is made available for use in the preparation of reports filed with the Securities and Exhange Commission pursuant to Rule 13f-1 [17 CFR 240.13f-1] under Section 13(f) of the Securities Exchange Act of 1934. An updated list is published on a quarterly basis. This list is current as of December 15, 2019, and may be relied on by institutional investment managers filing Form 13F reports for the calendar quarter ending December 30, 2019. Institutional investment managers should report holdings--number of shares and fair market value--as of the last day of the calendar quarter as required by [ Section 13(f)(1) and Rule 13f-1] thereunder. Features (1) Additions and Deletions: Revisions made to the list of Section 13(f) securities are indicated in a column titled “STATUS.” The word “ADDED” in the status column opposite the name of a security indicates that the security has become a Section 13(f) security. The word “DELETED” in the status column opposite the name of a security indicates that the security ceases to be a 13(f) security since the date of the last list. (2) List of options: An asterisk is placed next to the name of any security having a listed option and each option is individually listed with its own CUSIP number immediately below the name of the security having the option. A manager reporting holdings of options on its Form13F should use the CUSIP number of the underlying securities to which the option relates. CUSIP descriptions and numerical identification date (copyright 1969 through 2020, American Bankers Association) are used with permission. All rights are reserved. Run Date: 1/3/2020 ** List of Section 13F Securities ** Page 1 Run Time: 12:27 Year: 2019 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS B38564 10 8 * EURONAV NV ANTWERPEN SHS B38564 90 8 EURONAV NV ANTWERPEN CALL B38564 95 8 EURONAV NV ANTWERPEN PUT C0534L AA 3 AURORA CANNABIS INC DEBT 5.500% 2/2 C10268 AC 1 BLACKBERRY LTD DEBT 3.750%11/1 C8509Q AA 6 SSR MNG INC DEBT 2.500% 4/0 D18190 89 8 * DEUTSCHE BANK AG NAMEN AKT D18190 90 8 DEUTSCHE BANK AG CALL D18190 95 8 DEUTSCHE BANK AG PUT F21107 10 1 * CONSTELLIUM SE CL A SHS ADDED F21107 90 1 CONSTELLIUM SE CALL ADDED F21107 95 1 CONSTELLIUM SE PUT ADDED G0080J 10 4 ACT II GLOBAL ACQUISITION CO CL A SHS G0080J 11 2 ACT II GLOBAL ACQUISITION CO UNIT 04/30/2026 G0080J 12 0 ACT II GLOBAL ACQUISITION CO *W EXP 04/30/202 G0084W 10 1 * ADIENT PLC ORD SHS G0084W 90 1 ADIENT PLC CALL G0084W 95 1 ADIENT PLC PUT G01125 10 6 * AFYA LTD CL A COM G01125 90 6 AFYA LTD CALL G01125 95 6 AFYA LTD PUT G0120M 10 9 AGBA ACQUISITION LTD SHS G0120M 11 7 AGBA ACQUISITION LTD *W EXP 05/10/202 G0120M 12 5 AGBA ACQUISITION LTD RIGHT 05/10/2024 G0120M 13 3 AGBA ACQUISITION LTD UNIT 05/10/2024 G0129K 10 4 * AIRCASTLE LTD COM G0129K 90 4 AIRCASTLE LTD CALL G0129K 95 4 AIRCASTLE LTD PUT G0132V 10 5 AGM GROUP HOLDINGS INC SHS CL A G0176J 10 9 * ALLEGION PUB LTD CO ORD SHS G0176J 90 9 ALLEGION PUB LTD CO CALL G0176J 95 9 ALLEGION PUB LTD CO PUT G01767 10 5 * ALKERMES PLC SHS G01767 90 5 ALKERMES PLC CALL Run Date: 1/3/2020 ** List of Section 13F Securities ** Page 2 Run Time: 12:27 Year: 2019 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G01767 95 5 ALKERMES PLC PUT G0177J 10 8 * ALLERGAN PLC SHS G0177J 90 8 ALLERGAN PLC CALL G0177J 95 8 ALLERGAN PLC PUT G0232J 12 7 ALUSSA ENERGY ACQUISITION CO UNIT 10/31/2026 ADDED G0250X 10 7 * AMCOR PLC ORD G0250X 90 7 AMCOR PLC CALL G0250X 95 7 AMCOR PLC PUT G02602 10 3 * AMDOCS LTD SHS G02602 90 3 AMDOCS LTD CALL G02602 95 3 AMDOCS LTD PUT G0335L 10 2 * AMIRA NATURE FOODS LTD SHS DELETED G0335L 90 2 AMIRA NATURE FOODS LTD CALL DELETED G0335L 95 2 AMIRA NATURE FOODS LTD PUT DELETED G0335L 20 1 * AMIRA NATURE FOODS LTD SHS NEW ADDED G0335L 90 1 AMIRA NATURE FOODS LTD CALL ADDED G0335L 95 1 AMIRA NATURE FOODS LTD PUT ADDED G037AX 10 1 * AMBARELLA INC SHS G037AX 90 1 AMBARELLA INC CALL G037AX 95 1 AMBARELLA INC PUT G0408V 10 2 * AON PLC SHS CL A G0408V 90 2 AON PLC CALL G0408V 95 2 AON PLC PUT G04415 10 8 ANDINA ACQUISITION CORP III SHS G04415 11 6 ANDINA ACQUISITION CORP III UNIT 09/24/2020 G04415 12 4 ANDINA ACQUISITION CORP III *W EXP 07/31/202 G04415 13 2 ANDINA ACQUISITION CORP III RIGHT 07/31/2020 G0443N 10 7 AQUAVENTURE HLDGS LTD SHS G0450A 10 5 * ARCH CAP GROUP LTD ORD G0450A 90 5 ARCH CAP GROUP LTD CALL G0450A 95 5 ARCH CAP GROUP LTD PUT G04553 10 6 ARCO PLATFORM LTD COM CL A G0457F 10 7 * ARCOS DORADOS HOLDINGS INC SHS CLASS -A - G0457F 90 7 ARCOS DORADOS HOLDINGS INC CALL Run Date: 1/3/2020 ** List of Section 13F Securities ** Page 3 Run Time: 12:27 Year: 2019 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G0457F 95 7 ARCOS DORADOS HOLDINGS INC PUT G0464B 10 7 * ARGO GROUP INTL HLDGS LTD COM G0464B 90 7 ARGO GROUP INTL HLDGS LTD CALL G0464B 95 7 ARGO GROUP INTL HLDGS LTD PUT G0535E 10 6 ASIA PACIFIC WIRE & CABLE CO ORD G0585R 10 6 * ASSURED GUARANTY LTD COM G0585R 90 6 ASSURED GUARANTY LTD CALL G0585R 95 6 ASSURED GUARANTY LTD PUT G0602B 10 0 ATIF HOLDINGS LIMITED SHS G06207 11 5 * ATLAS FINANCIAL HOLDINGS INC SHS NEW G06207 90 5 ATLAS FINANCIAL HOLDINGS INC CALL G06207 95 5 ATLAS FINANCIAL HOLDINGS INC PUT G06242 10 4 * ATLASSIAN CORP PLC CL A G06242 90 4 ATLASSIAN CORP PLC CALL G06242 95 4 ATLASSIAN CORP PLC PUT G0684D 10 7 * ATHENE HLDG LTD CL A G0684D 90 7 ATHENE HLDG LTD CALL G0684D 95 7 ATHENE HLDG LTD PUT G0692U 10 9 * AXIS CAPITAL HOLDINGS LTD SHS G0692U 90 9 AXIS CAPITAL HOLDINGS LTD CALL G0692U 95 9 AXIS CAPITAL HOLDINGS LTD PUT G07025 20 1 AURIS MEDICAL HOLDING LTD SHS G0750C 10 8 * AXALTA COATING SYS LTD COM G0750C 90 8 AXALTA COATING SYS LTD CALL G0750C 95 8 AXALTA COATING SYS LTD PUT G0750W 20 3 * AXOVANT GENE THERAPIES LTD COM G0750W 90 3 AXOVANT GENE THERAPIES LTD CALL G0750W 95 3 AXOVANT GENE THERAPIES LTD PUT G0751N 10 3 * ATLANTICA YIELD PLC SHS G0751N 90 3 ATLANTICA YIELD PLC CALL G0751N 95 3 ATLANTICA YIELD PLC PUT G0772R 20 8 BANK OF NT BUTTERFIELD&SON L SHS NEW G0891M AA 4 BAOZUN INC DEBT 1.625% 5/0 G10830 10 0 BEYONDSPRING INC SHS Run Date: 1/3/2020 ** List of Section 13F Securities ** Page 4 Run Time: 12:27 Year: 2019 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G1117K 10 6 BIOCERES CROP SOLUTIONS CORP *W EXP 03/14/202 G1117K 11 4 BIOCERES CROP SOLUTIONS CORP SHS G11196 10 5 * BIOHAVEN PHARMACTL HLDG CO L COM G11196 90 5 BIOHAVEN PHARMACTL HLDG CO L CALL G11196 95 5 BIOHAVEN PHARMACTL HLDG CO L PUT G1151C 10 1 * ACCENTURE PLC IRELAND SHS CLASS A G1151C 90 1 ACCENTURE PLC IRELAND CALL G1151C 95 1 ACCENTURE PLC IRELAND PUT G1190F 10 7 BLUE CAP REINS HLDGS LTD COM G1329V 10 6 BLUE HAT INTERACTIVE ENTMT T SHS G1466B 10 3 BORQS TECHNOLOGIES INC SHS G1466R 20 7 BORR DRILLING LTD SHS G14838 10 9 * MIMECAST LTD ORD SHS G14838 90 9 MIMECAST LTD CALL G14838 95 9 MIMECAST LTD PUT G1611B 10 7 BROOGE HLDGS LTD SHS ADDED G1611B 11 5 BROOGE HLDGS LTD *W EXP 12/20/202 ADDED G16234 10 9 * BROOKFIELD BUSINESS PARTNERS UNIT LTD LP G16234 90 9 BROOKFIELD BUSINESS PARTNERS CALL G16234 95 9 BROOKFIELD BUSINESS PARTNERS PUT G16249 10 7 * BROOKFIELD PROPERTY PARTRS L UNIT LTD PARTN G16249 90 7 BROOKFIELD PROPERTY PARTRS L CALL G16249 95 7 BROOKFIELD PROPERTY PARTRS L PUT G16252 10 1 * BROOKFIELD INFRAST PARTNERS LP INT UNIT G16252 90 1 BROOKFIELD INFRAST PARTNERS CALL G16252 95 1 BROOKFIELD INFRAST PARTNERS PUT G16258 10 8 * BROOKFIELD RENEWABLE PARTNER PARTNERSHIP UNIT G16258 90 8 BROOKFIELD RENEWABLE PARTNER CALL G16258 95 8 BROOKFIELD RENEWABLE PARTNER PUT G16962 10 5 * BUNGE LIMITED COM G16962 90 5 BUNGE LIMITED CALL G16962 95 5 BUNGE LIMITED PUT G1757E 11 3 CALEDONIA MNG CORP PLC SHS NEW G17766 10 9 CAMBIUM NETWORKS CORP SHS Run Date: 1/3/2020 ** List of Section 13F Securities ** Page 5 Run Time: 12:27 Year: 2019 Qtr: 4 IVM001 CUSIP NO ISSUER NAME ISSUER DESCRIPTION STATUS G1890L 10 7 * CAPRI HOLDINGS LIMITED SHS G1890L 90 7 CAPRI HOLDINGS LIMITED CALL G1890L 95 7 CAPRI HOLDINGS LIMITED PUT G1991C 10 5 * CARDTRONICS PLC SHS CL A G1991C 90 5 CARDTRONICS PLC CALL G1991C 95 5 CARDTRONICS PLC PUT G1992S 10 9 * CISION LTD SHS G1992S 90 9 CISION LTD CALL G1992S 95 9 CISION LTD PUT G20045 20 2 * CENTRAL EUROPEAN MEDIA ENTRP CL A NEW G20045 90 2 CENTRAL EUROPEAN MEDIA ENTRP CALL G20045 95 2 CENTRAL EUROPEAN MEDIA ENTRP PUT G21082 10 5 * CHINA YUCHAI INTL LTD COM G21082 90 5 CHINA YUCHAI INTL LTD CALL G21082 95 5 CHINA YUCHAI INTL LTD PUT G2110U 10 9 CHINA NATURAL RESOURCES INC COM G2113X 13 4 CHINA CERAMICS CO LTD SHS G2118P 10 2 CHINA CUST RELATIONS CNTR IN COM G2120A 10 1 CHINA INTERNET NATIONWIDE FI SHS G2143T 10 3 * CIMPRESS
Load more

Recommended publications
  • Birks Group 2018 Annual Report
    ANNUAL REPORT 2018 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F ‘ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR È ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2018 OR ‘ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ‘ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of event requiring this shell company report For the transition period from to Commission file number: 001-32635 BIRKS GROUP INC. (Exact name of Registrant as specified in its charter) Not Applicable (Translation of Registrant’s name into English) Canada (Jurisdiction of incorporation or organization) 2020 Robert-Bourassa Blvd. Montreal Québec Canada H3A 2A5 (Address of principal executive offices) Pat Di Lillo, 514-397-2592 (telephone), 514-397-2537 (facsimile) 2020 Robert-Bourassa Blvd. Suite 200 Montreal Québec Canada H3A 2A5 (Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person) Securities registered or to be registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Class A Voting Shares, without nominal or par value NYSE American LLC Securities registered or to be registered pursuant to Section 12(g) of the Act: None. Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act: None. The number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the Annual Report was: 10,242,911 Class A Voting Shares, without nominal or par value 7,717,970 Class B Multiple Voting Shares, without nominal or par value 0 Series A Preferred Shares, without nominal or par value, issuable in series Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
    [Show full text]
  • By in Vivo's Biopharma, Medtech and Diagnostics Teams
    invivo.pharmaintelligence.informa.com JANUARY 2018 Invol. 36 ❚ no. 01 Vivopharma intelligence ❚ informa 2018 OUTLOOK By In Vivo’s Biopharma, Medtech and Diagnostics Teams PAGE LEFT BLANK INTENTIONALLY invivo.pharmaintelligence.informa.com STRATEGIC INSIGHTS FOR LIFE SCIENCES DECISION-MAKERS CONTENTS ❚ In Vivo Pharma intelligence | January 2018 BIOPHARMA MEDTECH 2018 DIAGNOSTICS OUTLOOK 12 22 28 Biopharma 2018: Medtech 2018: Diagnostics 2018: Is There Still A Place For Pharma The Place For Innovation Steady Progress And In The New Health Care As Value-based Health Care The Big Get Bigger Economy? Gains Momentum MARK RATNER WILLIAM LOONEY ASHLEY YEO If the beginning of 2017 was marked 2018 will be a time of transition in health 2017 was a watershed year in many by doubts around whether and how care, when biopharma’s counterparts respects, politically, economically the FDA would act with respect to in adjacent industry segments scale up and commercially for many players complex diagnostics, we enter 2018 in a radical redesign of their traditional in the medtech field. Where will the feeling that slow-moving vessel may business models. Biopharma is not opportunities lie in 2018? Will finally be turning. moving as quickly, and it confronts a breakthrough medtech innovation still strategic dilemma on how to address the have a place among providers often prospect of a much more powerful set of riding on fumes when it comes to 36 rivals in the ongoing battle to own the budgets, and is it all as bad as some patient experience in medicine. would make out? Thirty-five Years Covering Health Care: The More Things Change… 30 PETER CHARLISH A Virtuous Cycle: What The The health care industry has come a Immuno-Oncology Revolution long way in the past 35 years, although Means For Other Disease Areas in some areas very little has changed.
    [Show full text]
  • Preface Patrick Besha, Editor Alexander Macdonald, Editor in The
    EARLY DRAFT - NASAWATCH.COM/SPACEREF.COM Preface Patrick Besha, Editor Alexander MacDonald, Editor In the next decade, NASA will seek to expand humanity’s presence in space beyond the International Space Station in low-Earth orbit to a new habitation platform orbiting the moon. By the late 2020’s, astronauts will live and work far deeper in space than ever before. The push to cis-lunar orbit is part of a stepping-stone approach to extend our reach to Mars and beyond. This decision to explore ever farther destinations is a familiar pattern in the history of American space exploration. Another major pattern with historical precedent is the transition from public sector exploration to private sector commercialization. After the government has developed and demonstrated a capability in space, whether it be space-based communications or remote sensing, the private sector has realized its market potential. As new companies establish a presence, the government withdraws from the market. In 2015, we are once again at a critical stage in the development of space. The most successful long-term human habitation in space, orbiting the Earth continuously since 1998, is the International Space Station. Currently at the apex of its capabilities and the pinnacle of state-of-the-art space systems, it was developed through the investments and labors of over a dozen nations and is regularly re-supplied by cargo delivery services. Its occupants include six astronauts and numerous other organisms from Earth’s ecosystems from bacteria to plants to rats. Research is conducted on the spacecraft from hundreds of organizations worldwide ranging from academic institutions to large industrial companies and from high-tech start-ups to high-school science classes.
    [Show full text]
  • Dr. Wagner Vendrame CV
    W. Vendrame ________________________________________________________________________ Wagner A. Vendrame Professor, Environmental Horticulture Department Institute of Food and Agricultural Sciences University of Florida 2043 IFAS Research Dr., Gainesville, Fl 32611 Phone: 352-273-4500 (office), 786-202-0040 (cell) Email: [email protected] Website: http://hort.ufl.edu/faculty-profiles/wagner-vendrame/ EDUCATION University of Georgia Horticulture Ph.D. 1998 University of São Paulo Plant Physiology & Biochemistry M.S. 1994 University of São Paulo Agronomic Engineering B.S. 1987 EMPLOYMENT 2020-Present Professor and Assistant Chair, Environmental Horticulture Department, Gainesville, FL 2013-2020 Professor, Environmental Horticulture Department, Tropical Research and Education Center, University of Florida, Homestead, FL 2007-2013 Associate Professor, Environmental Horticulture Department, Tropical Research and Education Center, University of Florida, Homestead, FL 2001-2007 Assistant Professor, Environmental Horticulture Department, Tropical Research and Education Center, University of Florida, Homestead, FL 1998-2001 Post-Doctoral Associate, D. B. Warnell School of Forest Resources University of Georgia, Athens, GA RESEARCH ASSIGNMENT (60%) RESEARCH Improved Production and Conservation of Plants using Macro and Micropropagation, Bioreactor Technology, and Cryopreservation. 1 W. Vendrame ________________________________________________________________________ • Current research responsibilities include production and conservation of plants
    [Show full text]
  • Infectious Diseases
    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
    [Show full text]
  • Bigitech Fact Sheet 2017.12
    BlueStar Israel Global Technology IndexTM TM Q417 BIGITech Fact Sheet INDEX OVERVIEW The BlueStar Israel Global Technology IndexTM provides a benchmark for investors to track Israeli and Israel-linked technology companies trading worldwide. The index is constructed using BlueStar Indexes’ unique methodology and proprietary database of Israeli and Israel- linked companies. BIGITechTM is a modified market capitalization weighted index, capping the top-weighted constituents at 10%. It includes the largest and most liquid technology companies, as well as mid and small cap companies that display sufficient liquidity for global investors. The methodology allows for the inclusion of Israeli companies listed on the Tel Aviv Stock Exchange and other major exchanges such as the London Stock Exchange, New York Stock Exchange, and NASDAQ. Furthermore the methodology provides for the inclusion of companies that develop, manufacture, and/or deliver innovative technologies in a wide range of tech sectors, including Bio- Tech, Agriculture-Tech, Defense-Tech, Clean-Tech as well as Info-tech. Top Ten Index Constituents GICS Industry Exposure Company Index Weight (%) Industry Weight (%) Nice Ltd 7.63 Software 27.78 Amdocs Ltd 7.44 Semiconductors & Semiconductor 14.49 Check Point Software Tech 7.11 IT Services 10.15 Tower Semiconductor Ltd 4.66 Biotechnology 7.52 Elbit Systems Ltd 4.41 Internet Software & Services 5.47 Mellanox Technologies Ltd 4.26 Aerospace & Defense 5.45 Verint Systems Inc 3.89 Communications Equipment 5.24 Ormat Technologies Inc 3.52 Health Care Equipment & Suppli 4.86 Wix.Com Ltd 3.37 Independent Power and Renewabl 4.36 Orbotech Ltd 3.26 Electronic Equipment, Instrume 3.96 Total 49.52 Technology Hardware, Storage & 1.70 Diversified Financial Services 1.68 Pharmaceuticals 1.49 Hotels, Restaurants & Leisure 1.43 Machinery 1.38 BIGITech™ Internal Index Data Commercial Services & Supplies 0.69 Other 12.35 Index Statistics No.
    [Show full text]
  • 2018-2019 Annual Report
    2018-2019 annuAl report THE MONTREAL MUSEUM OF FINE ARTS CITED AS MODEL EXAMPLE IN THE OECD AND ICOM’S INTERNATIONAL GUIDE “The Organisation for Economic Co-operation and Development (OECD) and the International Council of Museums (ICOM) recognized the Montreal Museum of Fine Arts’ pioneering role in their guide launched in December 2018, Culture and Local Development: Maximising the Impact. Guide for Local Governments, Communities and Museums. This remarkable validation from two major international economic and cultural institutions will enable us to disseminate our message ever farther, so as to strengthen the role of culture and expand the definition of trailblazing museums, like the MMFA, that are fostering greater inclusion and wellness.” – Nathalie Bondil The Museum is cited in 5 of the 16 international case studies in the guide: a remarkable nod to our institution’s actions that stem from a humanist, innovative and inclusive vision. Below are a few excerpts from the publication that is available online at www.oedc.org: 1. Partnering for urban regeneration 3. Partnership for education: EducArt 5. Promoting inclusiveness, health and Regarding the MMFA’s involvement in creating the digital platform, Quebec, Canada well-being: A Manifesto for a Humanist Zone Éducation-Culture in 2016, in collaboration Launched in 2017 by the MMFA, EducArt gives Fine Arts Museum with Concordia University and the Ville de Montreal: secondary school teachers across the province access “As part of the Manifesto for a Humanist Fine “The project … has its roots in a common vision [of to an interdisciplinary approach to teaching the Arts Museum written by Nathalie Bondil,1 the the three institutions] to improve Montreal’s role as educational curriculum, based on the Museum’s MMFA has put forth a strong vision of the social a city of knowledge and culture.
    [Show full text]
  • Say on Pay Results (As of September 5)
    THIS REPORT CAN BE ACCESSED AT HTTP://WWW.SEMLERBROSSY.COM/SAYONPAY NOTE: THIS WILL BE OUR FINAL SAY ON PAY UPDATE FOR 2012. WE WILL ISSUE A FULL REPORT PROVIDING RESULTS FOR THE ENTIRE 2012 PROXY SEASON IN JANUARY 2013. PLEASE CONTINUE TO VISIT OUR SAY ON PAY BLOG FOR UPDATES. SAY ON PAY RESULTS 2012 RUSSELL 3000 SEPTEMBER 5 2012 SAY ON PAY RESULTS: RUSSELL 3000 SHAREHOLDER VOTING SUMMARY OF FINDINGS 2012 Vote Results (n=2,025) 2 The majority of companies continue to pass Say on Pay in 2012 with substantial shareholder support: — 1,466 companies (72%) passed with over 90% support — 381 companies (19%) passed with between 70% and 90% support — 125 companies (6%) passed with between 50% and 70% support — 53 companies (2.6%) in the Russell 3000 have failed Vote of the Week McKesson received a vote of 62%, a decline of 8% from 2011, amidst criticism from shareholders and 3 their advisors over high relative CEO pay and retirement benefits Vote Results by Industry Health Care companies have received proportionally less support than other industries, while 4 Consumer Staple and Financial companies have received the most support Vote Results and Market Value 5 There does not appear to be a strong correlation between a company’s market value and Say on Pay vote result How Vote Results Changed in 2012 6 Companies below 70% in 2011 have generally received increased vote support in 2012: — 26 of 30 companies that failed in 2011 have passed in 2012 — Companies between 50‐70% in 2011 have improved by an average of 13% in 2012 Vote results for companies
    [Show full text]
  • Market Cap Close ADV 1598 67Th Pctl 745,214,477.91 $ 23.96
    Market Cap Close ADV 1598 67th Pctl $ 745,214,477.91 $ 23.96 225,966.94 801 33rd Pctl $ 199,581,478.89 $ 10.09 53,054.83 2399 Ticker_ Listing_ Effective_ Revised Symbol Security_Name Exchange Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M AAMC Altisource Asset Management Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L AEL American Equity Inv Life Hldg Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L AHL ASPEN Insurance Holding Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
    [Show full text]
  • Advancing Cell Therapeutic Products for Clinical Use
    Advancing cell therapeutic products for clinical use 1 Proprietary data of Pluristem Therapeutics Inc. Forward Looking Statement This presentation concerning Pluristem Therapeutics may include forward- looking statements which represent Pluristem Therapeutics' expectations or beliefs regarding future events. I caution that such statements involve risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Consequently, all such forward-looking statements are qualified by the cautionary language and risk factors set forth in Pluristem Therapeutics' periodic and other reports filed with the SEC. There can be no assurance that the actual results, events or developments referenced in such forward-looking statements will occur or be realized. Pluristem Therapeutics assumes no obligation to update these forward- looking statements to reflect actual results, changes in assumptions or changes in factors affecting such forward-looking statements. www.pluristem.com 2 Proprietary data of Pluristem Therapeutics Inc. Corporate Overview • Cell therapy company (NasdaqCM: PSTI, TASE: PSTI) • Using off-the-shelf, placenta-derived cells to achieve both local and systemic therapeutic effects – no tissue matching needed • First-in-class 3D cell culturing technology allowing for efficient, controlled production of multiple cell products in commercial quantities – “the process is the product” • Active with regulators in the U.S., EU, S. Korea, Australia & Israel • Demonstrated safety and efficacy in 3 clinical studies (two Phase I and one Phase I/II study) 3 Proprietary data of Pluristem Therapeutics Inc. Financial Overview • Market Cap: ~ $200 million • Cash and marketable securities: $41 million (March, 2015) • No debt • Net burn: ~ $23 million • 165 employees (16 PhD, 4 MD) • IP Ownership: over 40 granted patents and ~150 pending applications 4 Proprietary data of Pluristem Therapeutics Inc.
    [Show full text]
  • Bluestar Israel Quarterly Update Q3 2013 Final.Pptx
    BlueStar Israel Equity Update Third Quarter 2013 Q2 2013 in Review & Second Half 2013 Outlook What’s Inside Ø Global developed market equities pulled back slightly in Q2 2013 while U.S. stocks, as measured by the S&P 500 index, bucked the trend and posted a rise of 2.91%. Ø The BlueStar Israel Global Index was down by 95 bps in Q2 2013 while the MSCI Israel and TA-100 indexes were down 4.16% and 2.76%, respectively. 1. The BlueStar Ø Israeli consumer stocks, which are correlated with both domestic consumption as well as consumer spending in Israel’s export markets, lead Israeli Global Equities in Q2, while the Israel Global financial and energy stocks, which lead the Israeli Global Equity market’s rebound from the Index in Q1 2012 lows, consolidated. 2013 Ø The Israeli government decided on a 2013 and 2014 budget that will result in tax increases and spending cuts and the Shekel’s sharp appreciation versus the dollar and euro eased a bit. 2-5. About the Ø Mellanox Technologies announced it will delist its shares from the Tel Aviv Stock Exchange and the TASE’s bid to be included in MSCI’s European regional indexes was declined. Both BlueStar Israel events sparked concern about the future of the local exchange. Also, Israeli corporate Global Index pyramids come under attack by The Committee on Increasing Competitiveness in the Economy and the Business Concentration Law. (including Risk/ Ø The Energy sector is asserting itself as a major player in the Israeli economy, natural gas Return Data) reserve estimates and oil estimates are rising, and the government has decided upon an export strategy, clearing up uncertainty and removing some of the risk factors associated with investing in that sector.
    [Show full text]
  • Ormat Technologies Inc
    ORMAT TECHNOLOGIES INC MEETING DATE Wed, 06 Nov 2019 13:00 TYPE EGM ISSUE DATE Fri, 25 Oct 2019 MEETING LOCATION 6140 Plumas Street, Reno, NV 89519 CURRENT INDICES PIRC Global SECTOR Electric services COMPANY OVERVIEW Ormat Technologies is a provider of renewable power and energy technology. The Company is based in Reno, Nevada, and has over 150 power plants. MEETING SPECIFIC INFORMATION Ordinary resolutions are approved by simple majority of the votes cast. PROPOSALS ADVICE 1 Board Proposal to Declassify the Board For It is considered that staggered elections do not pursue shareholders’ best interest, as they entrench the board against hostile takeovers. In this sense, the Board’s proposal is welcomed as it will introduce annual election for all directors of the board, which is considered to be best practice. 2 Adjourn Meeting Oppose The Board requests authority to adjourn the special meeting until a later date or dates, if necessary, in order to permit further solicitation of proxies if there are not sufficient votes at the time of the special meeting to approve the merger. An oppose vote is recommended to any adjournment or postponement of meetings if a sufficient number of votes are present to constitute a quorum. It is considered that where a quorum is present, the vote outcome should be considered representative of shareholder opinion. ORMAT TECHNOLOGIES INC 06 Nov 2019 EGM 1 of 5 BOARD AND COMMITTEE COMPOSITION (post-Meeting) INDEPENDENT BY DIRECTOR GENDER PIRC COMPANY BOARD AC RC NC SC TENURE Dan Falk M No Yes NED C M M - 14 Todd C.
    [Show full text]